** RBC Capital markets upgrades drugmaker Neurocrine Biosciences NBIX.O to "outperform" from "sector perform", trims PT to $137 from $138
** Brokerage expects NBIX's commercial franchise, particularly Ingrezza, to remain solid and durable in the long term, with relatively low exposure to FDA or tariff concerns
** Ingrezza is approved for treating involuntary movements in the face, tongue or other body parts related to Huntington's disease, a genetic brain disorder
** Brokerage sees potential upside in NBIX's pipeline, particularly with experimental drug osavampator, which has shown favorable antidepressive effects and says it could have a potential market size of $1.8 billion if successful
** As of last close, NBIX stock down 33.4% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。